1: Eisenberg DM, David RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997. JAMA 1998; 280: 1569–75.
2: Heptinstall S, White A, Williamson L, Mitchel. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1998; i: 1071–4.
3: De Weerdt CJ, Bootsma HPR, Hendriks. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 1998; 3: 225–30.
4: Jadad AR, Moore RA, Carrol D, Jenkinson C, Reynolds DJM, Gavaghan, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clin. Trials 1996; 17: 1–12.
5: Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1998; 291: 569–73.
6: Murphy JJ, Heptinstall S, Mitchell JRA. Randomized double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1998; i: 189–92.
7: Palevitch D, Earon G, Carasso. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: A double-blind placebo-controlled study. Phytother. Res. 1998; 11: 508–11.
8: Kuritzky A, Elhacham Y, Yerushalmi Z, Hering. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1998; 44(Suppl. 2): 293P.
9: Pfaffenrath V, Fischer M, Friede M, Heinneicke V, Zepelin HH. Clinical dose–response study for the investigation of efficacy and tolerability of. Tanacetum parthenium in migraine prophylaxis. Proceedings of Deutscher Schmerzkongress 1998.
10: Fetow CW, Avila JR. Complementary and Alternative Medicines. Springhouse: Philadelphia, 1999.
11: Boon H, Smith M. The Botanical Pharmacy. Kingston, Canada: Quarry Press, 1999.
12: Ernst E. Possible interactions between synthetic and herbal medicinal products. Part 1: a systematic review of the indirect evidence. Perfusion 2000; 13: 4–15.
13: Lininger SW. A–Z Guide to Drug–Herb–Vitamin Interactions. Rocklin, CA: Prima Publishing, 1999.
14: Newall CA, Anderson LA, Phillipson JD. Herbal Medicines. London: The Pharmaceutical Press, 1996.
15: Brinker R. Herb Contraindications and Drug Interactions. Sandy, OR: Eclectic Medical Publications, 1998.
16: Tfelt-Hansen P, Nielsen SL. Patient numbers needed in prophylactic migraine trials. Neuroepidemiology 1997; 6: 214–19.
17: Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. J. Pharm. Pharmacol. 1987; 39: 459–65.
18: Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. J. Pharm. Pharmacol. 1988; 40: 743–5.
19: Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins Leukotrienes Med. 1982; 8: 653–60.
20: Awang DVC. Prescribing therapeutic feverfew (Tanacetum parthenium (L.) Schultz Bip., syn. Chrysanthemum parthenium (L.) Bernh.). Integrative Med. 1998; 1: 11–13.
21: Goadsby PJ. How do the currently used prophylactic agents work in migraine?. Cephalalgia 1997; 17: 85–92.
22: Brown AMG, Edwards CM, Davey MR, Power B, Lowe KC. Pharmacological activity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.): Assessment by inhibition of human polymorphonuclear leucocyte chemiluminescence in-vitro. J. Pharm. Pharmacol. 1998; 49: 558–61.
23: Hendriks H, Bos R, Woerdenbag HJ. The essential oil of Tanacetum parthenium (L.) Schultz-Bip. Flavour Fragrance J. 1996; 11: 367–71.
24: Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and other medicinal plants. Lancet 1997; 350: 1598–9.
25: Brun J, Claustrat B, Saddier P, Chazor G. Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 1995; 15: 136–9.
26: Willigmann J, Freudenstein J. Production of a stable feverfew (Tanacetum parthenium) extract as an active substance for a pharmaceutical product. Scharper Brümmer 1999 (internal document).
27: Anderson D, Jenkinson PC, Dewdney RS, Blowers SD, Johnson ES, Kadam NP. Chromosomal aberrations and sister chromatid exchanges in lymphocytes and urine mutagenicity of migraine patients: a comparison of chronic feverfew users and matched non-users. Hum. Toxicol. 1988; 7: 145–52.
28: Burry JN. Compositae dermatitis in South Australia: Contact dermatitis from Chrysanthemum parthenium. Contact Dermatitis 1980; 6: 445.
29: Hausen BM, Osmundsen PE. Contact allergy to parthenolide in Tanacetum parthenium (L.) Schulz-Bip. (Feverfew, Asteraceae) and cross-reactions to related sesquiterpene lactone containing compositae species. Acta Derm. Venereol. 1983; 63: 308–14.
30: Johnson ES. Patients who chew chrysanthemum leaves. MIMS Mag. 1983; 15 05: 32–5.
31: Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991; 337: 867–72.
32: Ernst E, Pittler MH. Alternative therapy bias [letter]. Nature 1997; 385: 480.
33: Pittler MH, Abbot NC, Harkness EF, Ernst E. Location bias in controlled clinical trials of complementary medicine. J. Clin. Epidemiol. 2000; 53: 485–9.
34: Ernst E, ed. Herbal Medicine. A Concise Overview for Professionals. Oxford: Butterworth-Heinemann, 2000.